Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- DQ +9.5%, ARLP +5%, KDP +4.9%, BOH +2.7%, CORZ +2.3%, DEA +2.3%, SNOW +1.6% (guidance), PKX +1.5%
Other news:
- ZBIO +56.5% (results from the Phase 2 MoonStone trial of obexelimab)
- RNA +43.6% (Avidity Biosciences to be acquired by Novartis (NVS) for $72.00 per share)
- BBIO +9.7% (topline results from FORTIFY, the Company's Phase 3 pivotal study of BBP-418)
- FRMI +6.4% (announces historic nuclear deals securing lead position to initiate AP1000s)
- ABTC +6.2% (has acquired approximately 1,414 Bitcoin)
- FATE +6.1% (presents new clinical data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy)
- KYTX +5.8% (highlights potential of KYV-101 in Rheumatoid Arthritis with Phase 1 data from investigator-initiated trial presented at ACR Convergence 2025)
- AUTL +5.2% (presents clinical data updates at the American College of Rheumatology Convergence 2025)
- ATAI +4.7% (discloses amendment to share purchase agreement)
- PPTA +4.6% (enters $255 million strategic equity investment from Agnico Eagle (AEM) and JPMorganChase)
- ORBS +4.4% (entered into an amended and restated Sales Agreement on Oct 27)
- CGEM +4.3% (shares additional Preclinical B Cell depletion data for CLN-978 at ACR Convergence 2025)
- ARVN +4.2% (Presents Preclinical Data for ARV-806)
- FFAI +4% (weekly investor update)
- WTRG +3.3% (American Water Works and Essential Utilities (WTRG) to combine in an all-stock, tax-free merger with a pro forma market capitalization of approximately $40 billion and combined enterprise value of approximately $63 billion)
- KYMR +3.3% (presentation of new preclinical data for KT-579)
- ELAN +3.2% (FDA issues emergency use authorization for Elanco's Credelio; announced label expansions for two of its leading canine prescription parasiticides)
- CABA +2.8% (clinical data and development updates for Rese-cel at ACR Convergence 2025)
- NMRA +2.7% (preclinical data for NMRA-215)
- CADE +2.7% (Cadence Bank confirms it will be acquired by Huntington Bancshares)
- EVO +2.4% (announces progress in preclinical neuroscience partnership with Bristol Myers Squibb)
- GOGO +2.3% (COO to depart)
- GRND +2.3% (confirms receipt of take-private proposal from large shareholders)
- SEIC +1.6% (increases stock share repurchase program by $650 million)
- GH +1.6% (to share data supporting critical role of blood-based testing in improving cancer screening adherence at ACG 2025)
- PHAT +1.2% (publication of data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA improved nocturnal GERD symptoms in patients with non-erosive reflux disease)
- GSK +1.2% (acquires exclusive rights from Syndivia)